Quest Diagnostics

Quest Diagnostics integrated its Haystack MRD ctDNA test and Comprehensive Genomic Profiling services into Flatiron Health's OncoEMR platform via pilot with American Oncology Network, providing 4,700 clinicians at 1,600 U.S. cancer care locations direct access to advanced oncology testing within existing EHR workflows.

Leadership read: The operational shift here is not the test itself but the distribution architecture. Quest has moved advanced oncology diagnostics from a referral-out workflow, where ordering required clinicians to leave their primary system, into an embedded, point-of-care ordering experience inside OncoEMR. That changes the friction economics of adoption at community cancer sites, where time-to-order and cognitive load are the real barriers to advanced testing uptake. The pilot covering 4,700 clinicians across 1,600 locations means Quest has now committed to maintaining EHR-integrated data flows, test-result return logic, and clinical workflow compatibility at a scale that cannot be managed through a partnerships team alone. The related signals set for this period is thin for oncology diagnostics specifically; the 12 comparable product-launch signals tracked in the last 90 days are drawn from unrelated verticals including consumer beauty, residential solar, and fintech. There is no directly analogous lab-EHR integration signal to benchmark against, so the pattern read must come from context: EHR-embedded diagnostics is a structural direction that has been building across reference labs and health-system vendors since payer pressure on community oncology intensified, and Quest moving first at this network scale establishes a competitive integration standard others will be measured against. Companies operating at this intersection of clinical diagnostics and health-IT infrastructure face rising demand for leadership in health informatics, interoperability engineering, and commercial roles capable of structuring and expanding network-level partnerships rather than traditional payer or hospital-system sales. The move from test manufacturer to embedded clinical workflow provider is a functionally distinct business motion, and the talent required to sustain and scale it differs materially from the talent that built the underlying assay.

curated · 2026-07-17 · context →